Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
IM-1617 · 1 trial · 6 indications
Type, frequency, seriousness, and severity of adverse events (AEs) graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 6.0
Type, frequency, seriousness, and severity of adverse events (AEs) graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 6.0
Type, frequency, seriousness, and severity of adverse events (AEs) graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 6.0
Type, frequency, seriousness, and severity of adverse events (AEs) graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 6.0
| Arm | Type | Description |
|---|---|---|
| IM-1617 Dose Escalation | EXPERIMENTAL | IM-1617 given into the vein (IV; intravenously) |
| IM-1617 Monotherapy Dose Expansion | EXPERIMENTAL | IM-1617 given into the vein (IV; intravenously) |
| Name | Type | Description |
|---|---|---|
| IM-1617 | DRUG | IM-1617 is an antibody-drug conjugate |
Inclusion Criteria: 1. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2 2. Part A: Histological diagnosis of one of the following unresectable locally advanced or metastatic solid tumors: * CRC, all subtypes * NSCLC: * Non-squamous cell carcinoma subtypes, suc...
Top 20 of 80 competitors
IM-1617 is an investigational small molecule being developed by Immunome, Inc. for the treatment of advanced solid tumors, including colorectal cancer. It is a biomarker-selected therapy, meaning trial enrollment is guided by a specific molecular marker. IM-1617 is currently in Phase 1 clinical development and has not been approved by the FDA.
IM-1617 is being studied for use in colorectal cancer as part of a Phase 1 trial in participants with advanced cancer. The study also enrolls patients with non-small cell lung cancer, breast cancer, esophageal cancer, stomach cancer, and other cancers. IM-1617 is investigational and has not been approved for any indication.
IM-1617 is being developed by Immunome, Inc., a biopharmaceutical company that trades on the Nasdaq under the ticker symbol IMNM. Immunome is the sponsor of the ongoing Phase 1 study of IM-1617 in advanced solid tumors.
IM-1617 is in Phase 1 clinical development. The only registered trial of IM-1617 is a Phase 1 study that is currently recruiting participants. IM-1617 is investigational and has not received FDA approval.
IM-1617 is being evaluated in one clinical trial, NCT07578571, titled A Phase 1 Study of IM-1617 in Participants With Advanced Cancer. The trial is recruiting, is controlled, is not randomized or double-blind, and plans to enroll 175 participants aged 18 years and older in the United States.
Yes, 1617 is an alternative name for IM-1617, the investigational small molecule developed by Immunome, Inc. Both names refer to the same Phase 1 asset being studied in advanced solid tumors, including colorectal cancer, under the trial identifier NCT07578571.